RNS Number : 3413Z
Cambridge Cognition Holdings PLC
07 April 2026
7 April 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Notice of Results
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care will announce its results for the year ended 31 December 2025 on Monday 13 April 2026.
Enquiries:
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer
Tel: 01223 810700 press@camcog.com
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks
Tel:020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales
Singer Capital Markets Limited (Joint Broker) Amber Higgs /James Serjeant / Daniel Ingram
Tel: 020 7496 3000
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.
Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:
Clinical Studies for new pharmaceuticals;
Academic Research for scientists to understand CNS disorders;
Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.
For further information, visit: www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBRGDSXXGDGLD
